Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox

Free Radical Biology and Medicine

Volumn 53, Issue 4, 2012, Pages 643-648

  Kikuchi, Shohei ^a   Kobune, Masayoshi ^a   Iyama, Satoshi ^a   Sato, Tsutomu ^a   Murase, Kazuyuki ^a   Kawano, Yutaka ^a   Takada, Kohichi ^a   Ono, Kaoru ^a   Kaneko, Yumiko ^a   Miyanishi, Koji ^a   Sato, Yasushi ^a   Hayashi, Tsuyoshi ^a   Takimoto, Rishu ^a   Kato, Junji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Iron chelation; Myelodysplastic syndrome; Oxidative DNA damage

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DEFERASIROX; FERRITIN;

ARTICLE; CHELATION THERAPY; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DNA DAMAGE; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HUMAN; IRON CHELATION; MYELODYSPLASTIC SYNDROME; OXIDATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTIGENS, CD; BENZOATES; CASE-CONTROL STUDIES; DEOXYGUANOSINE; DNA DAMAGE; ERYTHROCYTE TRANSFUSION; FERRITINS; GENOME, HUMAN; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LEUKOCYTES, MONONUCLEAR; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; STATISTICS, NONPARAMETRIC; TRIAZOLES;

EID: 84864401567     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.06.006     Document Type: Article

References (46)

1. P. Greenberg, C. Cox, M.M. LeBeau, P. Fenaux, P. Morel, G. Sanz, M. Sanz, T. Vallespi, T. Hamblin, D. Oscier, K. Ohyashiki, K. Toyama, C. Aul, G. Mufti, and J. Bennett International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088
2. L. Malcovati, M.G. Porta, C. Pascutto, R. Invernizzi, M. Boni, E. Travaglino, F. Passamonti, L. Arcaini, M. Maffioli, P. Bernasconi, M. Lazzarino, and M. Cazzola Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J. Clin. Oncol 23 2005 7594 7603
3. K. Sridhar, D.T. Ross, R. Tibshirani, A.J. Butte, and P.L. Greenberg Relationship of differential gene expression profiles in CD34 myelodysplastic syndrome marrow cells to disease subtype and progression Blood 114 2009 4847 4858
4. A. Mohamedali, J. Gaken, N.A. Twine, W. Ingram, N. Westwood, N.C. Lea, J. Hayden, N. Donaldson, C. Aul, N. Gattermann, A. Giagounidis, U. Germing, A.F. List, and G.J. Mufti Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes Blood 110 2007 3365 3373
5. P.L. Bergsagel, and W.M. Kuehl Comprehensive identification of somatic mutations in chronic lymphocytic leukemia Cancer Cell 20 2011 5 7
6. F. Thol, I. Friesen, F. Damm, H. Yun, E.M. Weissinger, J. Krauter, K. Wagner, A. Chaturvedi, A. Sharma, M. Wichmann, G. Gohring, C. Schumann, G. Bug, O. Ottmann, W.K. Hofmann, B. Schlegelberger, M. Heuser, and A. Ganser Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes J. Clin. Oncol. 29 2011 2499 2506
7. G. Nikoloski, S.M. Langemeijer, R.P. Kuiper, R. Knops, M. Massop, E.R. Tonnissen, A. van der Heijden, T.N. Scheele, P. Vandenberghe, T. de Witte, B.A. van der Reijden, and J.H. Jansen Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes Nat. Genet. 42 2010 665 667
8. M.S. Davids, and D.P. Steensma The molecular pathogenesis of myelodysplastic syndromes Cancer Biol. Ther. 10 2010 309 319
9. Y. Imai, M. Kurokawa, K. Izutsu, A. Hangaishi, K. Takeuchi, K. Maki, S. Ogawa, S. Chiba, K. Mitani, and H. Hirai Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis Blood 96 2000 3154 3160
10. M.J. Walter, L. Ding, D. Shen, J. Shao, M. Grillot, M. McLellan, R. Fulton, H. Schmidt, J. Kalicki-Veizer, M. O'Laughlin, C. Kandoth, J. Baty, P. Westervelt, J.F. Dipersio, E.R. Mardis, R.K. Wilson, T.J. Ley, and T.A. Graubert Recurrent DNMT3A mutations in patients with myelodysplastic syndromes Leukemia 25 2011 1153 1158
11. J. Rocquain, N. Carbuccia, V. Trouplin, S. Raynaud, A. Murati, M. Nezri, Z. Tadrist, S. Olschwang, N. Vey, D. Birnbaum, V. Gelsi-Boyer, and M.J. Mozziconacci Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias BMC Cancer 10 2010 401
12. M.H. Raaijmakers, S. Mukherjee, S. Guo, S. Zhang, T. Kobayashi, J.A. Schoonmaker, B.L. Ebert, F. Al-Shahrour, R.P. Hasserjian, E.O. Scadden, Z. Aung, M. Matza, M. Merkenschlager, C. Lin, J.M. Rommens, and D.T. Scadden Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia Nature 464 2011 852 857
13. T. Schmidt, B. Kharabi Masouleh, S. Loges, S. Cauwenberghs, P. Fraisl, C. Maes, B. Jonckx, K. De Keersmaecker, M. Kleppe, M. Tjwa, T. Schenk, S. Vinckier, R. Fragoso, M. De Mol, K. Beel, S. Dias, C. Verfaillie, R.E. Clark, T.H. Brummendorf, P. Vandenberghe, S. Rafii, T. Holyoake, A. Hochhaus, J. Cools, M. Karin, G. Carmeliet, M. Dewerchin, and P. Carmeliet Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1() leukemia Cancer Cell 19 2011 740 753
14. A.M. Marcondes, A. Ramakrishnan, and H.J. Deeg Myeloid malignancies and the marrow microenvironment: some recent studies in patients with MDS Curr. Cancer Ther. Rev 5 2009 310 314
15. H. Ye, and T.A. Rouault Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease Biochemistry 49 2010 4945 4956
16. M. Diehn, R.W. Cho, N.A. Lobo, T. Kalisky, M.J. Dorie, A.N. Kulp, D. Qian, J.S. Lam, L.E. Ailles, M. Wong, B. Joshua, M.J. Kaplan, I. Wapnir, F.M. Dirbas, G. Somlo, C. Garberoglio, B. Paz, J. Shen, S.K. Lau, S.R. Quake, J.M. Brown, I.L. Weissman, and M.F. Clarke Association of reactive oxygen species levels and radioresistance in cancer stem cells Nature 458 2009 780 783
17. K. Ito, A. Hirao, F. Arai, K. Takubo, S. Matsuoka, K. Miyamoto, M. Ohmura, K. Naka, K. Hosokawa, Y. Ikeda, and T. Suda Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells Nat. Med 12 2006 446 451
18. E. Nitta, M. Yamashita, K. Hosokawa, M. Xian, K. Takubo, F. Arai, S. Nakada, and T. Suda Telomerase reverse transcriptase protects ATM-deficient hematopoietic stem cells from ROS-induced apoptosis through a telomere-independent mechanism Blood 117 2011 4169 4180
19. A. Sallmyr, J. Fan, and F.V. Rassool Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair Cancer Lett 270 2008 1 9
20. M. Takatoku, T. Uchiyama, S. Okamoto, Y. Kanakura, K. Sawada, M. Tomonaga, S. Nakao, T. Nakahata, M. Harada, T. Murate, and K. Ozawa Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality Eur. J. Haematol 78 2007 487 494
21. K. Miyazawa, K. Ohyashiki, A. Urabe, T. Hata, S. Nakao, K. Ozawa, T. Ishikawa, J. Kato, Y. Tatsumi, H. Mori, M. Kondo, J. Taniguchi, H. Tanii, L. Rojkjaer, and M. Omine A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a phase I study in Japan Int. J. Hematol 88 2008 73 81
22. S. Mahesh, Y. Ginzburg, and A. Verma Iron overload in myelodysplastic syndromes Leuk. Lymphoma 49 2008 427 438
23. N. Gattermann, C. Finelli, M.D. Porta, P. Fenaux, A. Ganser, A. Guerci-Bresler, M. Schmid, K. Taylor, D. Vassilieff, D. Habr, G. Domokos, B. Roubert, and C. Rose Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study Leuk. Res 34 2010 1143 1150
24. A.F. Remacha, B. Arrizabalaga, C. Del Canizo, G. Sanz, and A. Villegas Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements Ann. Hematol 89 2010 147 154
25. F. Wimazal, T. Nosslinger, C. Baumgartner, W.R. Sperr, M. Pfeilstocker, and P. Valent Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes Eur. J. Clin. Invest. 39 2009 406 411
26. G. Metzgeroth, D. Dinter, B. Schultheis, A. Dorn-Beineke, K. Lutz, O. Leismann, R. Hehlmann, and J. Hastka Deferasirox in MDS patients with transfusion-caused iron overload - a phase-II study Ann. Hematol 88 2009 301 310
27. J. Porter, R. Galanello, G. Saglio, E.J. Neufeld, E. Vichinsky, M.D. Cappellini, N. Olivieri, A. Piga, M.J. Cunningham, D. Soulieres, N. Gattermann, G. Tchernia, J. Maertens, P. Giardina, J. Kwiatkowski, G. Quarta, M. Jeng, G.L. Forni, M. Stadler, H. Cario, L. Debusscher, M. Della Porta, M. Cazzola, P. Greenberg, G. Alimena, B. Rabault, I. Gathmann, J.M. Ford, D. Alberti, and C. Rose Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study Eur. J. Haematol. 80 2008 168 176
28. M.D. Cappellini, J. Porter, A. El-Beshlawy, C.K. Li, J.F. Seymour, M. Elalfy, N. Gattermann, S. Giraudier, J.W. Lee, L.L. Chan, K.H. Lin, C. Rose, A. Taher, S.L. Thein, V. Viprakasit, D. Habr, G. Domokos, B. Roubert, and A. Kattamis Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion- dependent anemias Haematologica 95 2010 557 566
29. C. Rose, S. Brechignac, D. Vassilief, L. Pascal, A. Stamatoullas, A. Guerci, D. Larbaa, F. Dreyfus, O. Beyne-Rauzy, M.P. Chaury, L. Roy, S. Cheze, P. Morel, and P. Fenaux Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies) Leuk. Res 34 2010 864 870
30. H.A. Leitch Controversies surrounding iron chelation therapy for MDS Blood Rev. 25 2011 17 31
31. Kikuchi, S.; Kobune M.; Iyama S.; Sato T.; Murase K.; Kawano Y.; Takada K.; Ono K.; Hayashi T.; Miyanishi K.; Sato Y.; Takimoto R.; Kato J. Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome. Int. J. Hematol.; 2012.
32. T. Suzuki, M. Tomonaga, Y. Miyazaki, S. Nakao, K. Ohyashiki, I. Matsumura, Y. Kohgo, Y. Niitsu, S. Kojima, and K. Ozawa Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes Int. J. Hematol 88 2008 30 35
33. J. Kato, M. Kobune, S. Ohkubo, K. Fujikawa, M. Tanaka, R. Takimoto, K. Takada, D. Takahari, Y. Kawano, Y. Kohgo, and Y. Niitsu Iron/IRP-1-dependent regulation of mRNA expression for transferrin receptor, DMT1 and ferritin during human erythroid differentiation Exp. Hematol 35 2007 879 887
34. Y. Sato, K. Murase, J. Kato, M. Kobune, T. Sato, Y. Kawano, R. Takimoto, K. Takada, K. Miyanishi, T. Matsunaga, T. Takayama, and Y. Niitsu Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone Nat. Biotechnol 26 2008 431 442
35. J. Kato, M. Kobune, T. Nakamura, G. Kuroiwa, K. Takada, R. Takimoto, Y. Sato, K. Fujikawa, M. Takahashi, T. Takayama, T. Ikeda, and Y. Niitsu Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet Cancer Res 61 2001 8697 8702
36. M. Honda, Y. Yamada, M. Tomonaga, H. Ichinose, and S. Kamihira Correlation of urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study Leuk. Res 24 2000 461 468
37. A.M. Jankowska, L.P. Gondek, H. Szpurka, Z.P. Nearman, R.V. Tiu, and J.P. Maciejewski Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome Leukemia 22 2008 551 558
38. B. Novotna, Y. Bagryantseva, M. Siskova, and R. Neuwirtova Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome Leuk. Res 33 2009 340 343
39. K. Ito, K. Takubo, F. Arai, H. Satoh, S. Matsuoka, M. Ohmura, K. Naka, M. Azuma, K. Miyamoto, K. Hosokawa, Y. Ikeda, T.W. Mak, T. Suda, and A. Hirao Regulation of reactive oxygen species by Atm is essential for proper response to DNA double-strand breaks in lymphocytes J. Immunol 178 2007 103 110
40. C.I. Kobayashi, and T. Suda Regulation of reactive oxygen species in stem cells and cancer stem cells J. Cell Physiol 2011
41. A.S. Watson, M. Mortensen, and A.K. Simon Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia Cell Cycle 10 2011 1719 1725
42. M. Kobune, Y. Xu, C. Baum, M.R. Kelley, and D.A. Williams Retrovirus-mediated expression of the base excision repair proteins, formamidopyrimidine DNA glycosylase or human oxoguanine DNA glycosylase, protects hematopoietic cells from N,N′,N″- triethylenethiophosphoramide (thioTEPA)-induced toxicity in vitro and in vivo Cancer Res 61 2001 5116 5125
43. P.L. Greenberg, C.A. Koller, Z.I. Cabantchik, G. Warsi, T. Glynos, C. Paley, and C. Schiffer Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes Leuk. Res 34 2010 1560 1565
44. A.F. List, M.R. Baer, D.P. Steensma, A. Raza, J. Esposito, N. Martinez-Lopez, C. Paley, J. Feigert, and E. Besa Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome J. Clin. Oncol 2012 [Epub Ahead]
45. P. Fenaux, and C. Rose Impact of iron overload in myelodysplastic syndromes Blood Rev. 23 Suppl. 1 2009 S15 S19
46. R.S. Komrokji, N.H. Al Ali, E. Padron, J.F. Lancet, and A.F. List Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the Moffitt Cancer Center Blood 118 2011 2776a